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Background: Family-planning service delivery has been neglected; rigorous analyses of the patterns 
of contraceptive provision are needed to inform strategies to address this neglect. 
 
Methods: We used 57 nationally-representative Demographic and Health Surveys in low- and 
middle-income countries (2000-2013) to estimate need for contraceptive services, and examine the 
sector of provision, by socioeconomic position. We also assessed method-mix and whether women 
were informed of side-effects.  
 
Results: Modern contraceptive use among women in need was lowest in Sub-Saharan Africa (39%), 
with other regions ranging from 64-72%. The private-sector share of the family planning market was 
37-39% of users across the regions and 37% overall, (median across countries: 41%). Private-sector 
users accessed medical providers (range across regions: 30-60%; overall mean: 54%; median across 
countries 23%), specialised drug sellers (range across regions: 31-52%; overall mean: 36%; median 
across countries: 43%), and retailers (range across regions: 3-14%; overall mean: 6%; median across 
countries: 6%). Private retailers played a more important role in Sub-Saharan Africa (14%) than in 
other regions (3-5%). NGOs and FBOs served a small percentage.  
 
More privileged women (richest wealth-quintile, urban residents, or secondary/tertiary-level education) 
used private services more than the less privileged. Method-types with higher requirements (medical 
skills) for provision were less likely to be acquired from the private sector, while short-acting 
methods/injectables were more likely. The percentages of women informed of side-effects varied by 
method and provider sub-type, but within these, were higher among public medical compared to 
private medical providers for four of five methods assessed.  
 
Conclusion: Given the importance of private-sector providers, we need to understand why women 
choose their services, what quality services the private sector provides and how it can be improved. 
However, when prioritising a relatively higher focus on one of the two sectors (public versus private), it 






Public and non-governmental family planning programmes have existed in many low- and middle-
income countries since as early as the 1950s, but contraceptive provision has been relatively 
neglected for nearly two decades[1]. In 2012, reinvigorated commitment was made to address family 
planning coverage, with $2.6 billion pledged by donors at the London Summit on Family Planning[2]. 
Stakeholders expressed the need for a range of approaches for delivering family planning services 
across all sectors, with a key research priority being the “effect of engaging [the] private sector to 
increase the equity in access to – and utilization of – family planning products and services, by 
modalities such as franchising and social marketing”[3]. Describing the different public and private 
modalities currently contributing to family planning coverage, and comparing the equity and the 
content of services by provider type, is a fundamental first step in meeting this objective[4]. 
 
Family planning use across multiple countries has been described previously [5-18], but fewer studies 
have examined the sector in which women seek services. Using a search strategy published 
previously[19], we identified eight peer-reviewed papers[20-27] and twelve grey literature reports[28-
39] that examine provision by sector across multiple countries. The characteristics and findings of 
these studies are described in Web Table 1. The studies use between one to three sub-categories of 
private-sector providers, employing a variety of provider categories and definitions, with non-
governmental organisations and “others” in particular being grouped inconsistently. Six studies 
[20,26,28-31] use data entirely from before 2000, so their findings are dated. The remaining 14 
studies include at least some data from 2000 onwards, with between 4 and 56 countries studied. Nine 
of these fourteen studies include fewer than 15 countries; the remaining five studies[24,34-36,38] are 
large (25-56 countries), but are primarily tabulations, with little analysis or interpretation, and all bar 
one[24] are grey literature. Thirteen studies assess socioeconomic inequalities by sector 
[20,21,25,27,29-31,33-38]: three proxy socioeconomic status using residence and education [29-31], 
while two added employment[20] or wealth[36] to residence and education. The remaining eight 
studies look only at wealth quintiles for at least one sector or one country, and three of these use 
inequality metrics such as concentration indices or high-to-low equity ratios or differences. None of 
the population-based studies reviewed compared quality of services received by sector, probably 
because survey programmes contain few measures with which to assess quality of provision. The 
literature reporting on technical-quality or client satisfaction differences is generally facility-
based[40,41] or uses bespoke data collection instruments in a limited number of settings [42]. 
 
In this paper, we used the Demographic and Health Survey (DHS) to describe family planning use in 
57 low- and middle-income countries in detail, with a focus on the relative roles of the public and 
private sectors. Results are presented in total and by socioeconomic group (wealth quintile, 
urban/rural residence, and education), and by world region and country. We went beyond previous 
literature to describe where women obtained contraception by sector (distinguishing between seven 
sub-types of public and private providers) as well as the types of contraceptive methods used. We 
also described whether women were informed of side-effects as proxies for content and quality of 
care. This paper links to a Series on private-sector provision of family planning and maternal/newborn 
services, including an overview comparing provision across the different services[19], two in-depth 





The DHS are cross-sectional, nationally-representative household surveys[46]. Respondents are 
women of reproductive age (15-49 years), with men also interviewed in many surveys. The DHS 
measure household and individual characteristics, fertility and family planning, and maternal and child 
health and healthcare use. We used the most recent DHS (from 2000 to mid-2013); since 2000, the 
DHS improved how it captured sources of provision, particularly private provision. 
 
Populations and women in need of healthcare services 
We looked at three populations of women[19]: 1) all those surveyed; 2) those “in need” of family 
planning, and 3) those who used an “appropriate service type”, termed women with “met need”. Need 




In eight countries, surveyed women were “ever-married” rather than “all women” of reproductive age 
(Web Table 2). We categorised women “in need” of family planning according to a recently-updated 
consensus definition[47]. Women not in need of family planning methods were those not using any 
modern methods (defined in Table 1) who either desired a birth within two years or were not at risk of 
pregnancy (have never had sex, are not having sex [not married/no sex within the last 30 days], or 
were infecund or menopausal). The remainder were women who needed family planning. These were 
further stratified into those who used traditional methods (defined in Table 1), used modern methods 
or were not using any method. 
 
We considered women to have received an appropriate service (i.e., have met need for an 
appropriate family planning service) if they used a method broadly understood to be effective, though 
this does not imply that the actual quality-of-care received was appropriate or that the method was 
used correctly. All studies in our literature review defined family planning as use of modern 
contraceptive methods, irrespective of where they were obtained. We adopted this convention, as well 
as one that groups women using lactational amenorrhea method (LAM) or fertility awareness methods 
with users of traditional methods, even if they obtained/learned of the method from a provider. 
Women using LAM, fertility awareness and traditional methods, together with women not using any 
method, were consequently deemed to have unmet need for modern contraception (Table 1). 
 
Categorisation of source and sector of provision 
We classified the most recent source and sector of family planning provision as described in Table 1 
and previously [19,45]. Across the 57 countries, when we collated all response options and removed 
duplicates, the surveys included 141 unique family planning provider types: 49 that were in the public 
sector, 64 in the private-sector and 28 that could not be classified, namely women obtaining methods 
from husbands/relatives/friends, “other sources”, providers abroad, or with a missing source. In the 
public sector, providers were differentiated into public medical and public non-medical. In the private 
sector, they were differentiated into: private medical, private specialised drug seller, private retailer, 
faith-based organisation (FBO), and non-governmental organisation (NGO). The first three private-
sector provider categories were assumed to be commercial. 
 
Content and quality: categorisation of types of methods and assessing advice on side-effects  
The DHS contain few questions with which to assess content or quality-of-care of family planning 
provision. We examined the types of contraceptive methods provided (method mix) and advice given 
on side-effects as proxies for assessing quality-of-care, by provider category, sector and method.  
 
We sought expert advice from Marie Stopes International (who train providers and provide a complete 
range of contraceptives in many countries) on the skill-level and amount of training required to provide 
different contraceptives, and the actual time (excluding counselling) needed to dispense/give each 
method to users. Using this information, we grouped contraceptives into method types: 1) “easy” (no 
clinical skills required), 2) “medium” (some clinical skill required) and 3) “intensive” (clinical skill 
required) (Web Table 3). These also largely matched the categorisation of 1) “short-acting”, 2) “long-
acting reversible”, and 3) “permanent” methods [34,48] (Web Table 3), differing only in the 
classification of injectables, which were in our 2) “medium” category but in the other classification’s 1) 
“short-acting” category. We ultimately decided on four sub-categories, so that injectables could be 
viewed separately and considered with either “short-acting reversible” or with “medium” (some clinical 
skill required) methods. 
 
In each country, questions on whether women were advised on side-effects differed in the range of 
methods inquired about, and in the time elapsed since initiation of the method. We created a data-set 
of 46 countries which maximized the number of countries available for analyses of side-effect advice, 
while retaining comparable data (Web Table 2). These 46 countries all asked women who were 
currently using pills, injectables, implants, IUDs, or sterilisation, where they first obtained their current 
method, and whether at the time of first use, they were informed of side-effects or problems they 
might experience with the method, with yes or no response-options. Many countries restricted these 
questions to women who had initiated their current methods in the five years preceding the survey, so 
we applied this five-year cut-off to the entire sub-set of countries. We then categorised the first source 
of current method by sector and provider sub-type as shown in Table 1 and explored information 
about counselling by method, by source, and by method within provider sub-types with >1,000 users 
for each of the five methods, while recognising that these responses may not reflect the women’s 





The DHS generally have below 1% missing data, but the Turkish survey only collected fertility 
preferences (which are required to classify unmet-need status) on a random sub-sample of women. 
We assumed non-sampled women were missing data completely at random and imputed their 
fertility preferences, applying the same response distribution as those who were sampled, within 
each wealth quintile. In all other surveys, missing data on need were negligible and classed as “don't 
use, don't know need status”, a category which was excluded when examining the subset of “women 
in need”. There were no missing data on use of family planning among women in need. Users of 
modern methods whose provider was missing, or whose sector of provision was unclassifiable, were 
shown separately (Table 1). Users missing information on side-effect advice (2% of analysis sample) 
were excluded from the denominator. 
 
Categorisation of socioeconomic position 
We stratified our data by three measures of socioeconomic position: wealth quintiles derived by DHS 
using principal component analysis [49,50], urban/rural residence, and level of education. We used 
DHS classifications for wealth (except for Nicaragua and Peru where we constructed our own)[19], 
women’s highest achieved level of education (“no education”, “primary”, “secondary”, and “higher”) 
and urban/ rural residence. 
 
Categorisation of geographic regions and overall summary measures 
Women in each DHS survey have individual sample-weights used to calculate country-level 
population-representative summary statistics. We grouped countries into regions as previously 
described[19], adopting an approach used by others [51] . For simplicity, we refer to the regions as 
Sub-Saharan Africa, Middle East/Europe, Asia, and Latin America. We recognise that this 
categorisation is to some degree arbitrary, that there is considerable variation within regions, and that 
other possible groupings could have been used. In particular, the Middle East region, and to a lesser 
extent the Latin America & Caribbean region, include very diverse countries. We also show data by 
individual country to enable others to generate alternative groupings (Web Table 4). We calculated 
region-level and overall (combining the 57 countries or 46 countries for analysis of side-effect advice) 
summary statistics by applying weights that accounted for both the country-specific survey design and 
the country population (using 2008 UN Population Estimates[52]), to ensure that estimates 
represented the entire population residing in the study countries. Regional and overall summaries 
were thus weighted averages of country summaries. Non-parametric summary measures (medians 
and ranges across included countries) are also presented to describe the variability in country 
profiles. The countries are listed in Web Table 2. Countries without DHS data were excluded from the 
regional weighting. Analyses were conducted in Stata/SE v13.  
 
Ethical approval 
The DHS receive government permission, use informed consent and assure respondents of 
confidentiality. The Research Ethics Committee of the London School of Hygiene and Tropical 




We obtained data on 865,547 women aged 15-49 years from 57 countries, representing a total 
population of 3 billion people (46 countries, and 1.2 billion for advice given on side-effects). The 
numbers of countries and the proportions of the regions represented are in Table 2.  
 
Patterns 
Need among all women: Figure 1.a illustrates need and family-planning use status among all women, 
for each geographic region. Figures 1.b-1.d show the same results by wealth quintile, educational 
level, and urban/rural residence. The percentages of women of reproductive age needing 
contraception were substantial, with 39% of women surveyed being in need in Sub-Saharan Africa, 
compared to roughly 60% in the other three regions (Middle East/Europe 63%, Asia 58%, and Latin 
America 60%). In Sub-Saharan Africa, 26% wanted a child in the next two years, compared to 11% in 
Middle East/Europe, 14% in Asia, and 6% in Latin America; the overall mean was 16% and the 
median across countries was 13%. These data and the range across countries are also in Table 3; 
the remainder of women not in need were not at risk of pregnancy, either because they were not 




Use among all women and met need (use among women who need services): The percentages of all 
surveyed women using modern contraception were: Sub-Saharan Africa 15%, Middle East/Europe 
40%, Asia 39%, and Latin America 43%, and 34% overall (median across countries: 23%). The 
percentages of women in need using modern contraception were: Sub-Saharan Africa 39%, Middle 
East/Europe 64%, Asia 67%, and Latin America 72%, and 63% overall (median across countries: 
46%). Unmet need (100% minus the percentage of met need) for family planning was thus highest in 
Sub-Saharan Africa (61%). 
 
Private sector use among women in need: Figures 2.a-2.d show family planning by sector among 
women in need, for each region in total, and by measures of socioeconomic position. The private 
sector served 14% of women in need of contraception in Sub-Saharan Africa compared to about 25% 
in the other three regions (Middle East/Europe, 23%, Asia, 24%, and Latin America, 27%, and 22% 
overall; median across countries: 16%). 
 
Private use among classifiable service users: Figures 3.a-3.d show the type of service provider 
among women using modern methods, for each of the four regions in total, and by socioeconomic 
position. Among users of modern methods of contraception from classifiable sources, the 
percentages using private providers were: Sub-Saharan Africa 38%, Middle East/Europe 37%, Asia 
37%, Latin America 39%, and overall 37%; median across countries: 41%. 
 
Types of providers within the public and private sectors: Among women obtaining their methods from 
the public sector, nearly all obtained them from the public medical sector, with only <1% of women in 
Sub-Saharan Africa, Middle East/Europe or Latin America, and 5% in Asia obtaining them from 
public-sector non-medical providers (Table 3). Figures 4.a-4.d show provider sub-types among 
women using private providers to obtain modern contraception, for each of the four regions in total, 
and by socioeconomic-position. Among women obtaining their modern contraceptives from private-
sector providers, the percentage using private medical providers was: Sub-Saharan Africa 30%, 
Middle East/Europe 41%, Asia 60%, Latin America 45%, and overall 54%; median across countries: 
23%. Commercial sources (private medical, private specialised drug sellers and private retailers 
combined) dominated private-sector provision: Sub-Saharan Africa 91%, Middle East/Europe, 97%, 
Asia 96% and Latin America 96% (overall mean: 96%; median across countries: 99%). 
 
Inequalities 
Inequalities in risk of pregnancy, wanting children in the next two years, and needing contraception 
among all women and inequalities in use (met need and private-sector use among women in need) by 
wealth quintile are shown in Figures 1.b-3.b. In brief, there was a very slight gradient in need by 
wealth quintile in Sub-Saharan Africa and in Middle East/Europe, whereby the richest expressed the 
greatest need. In Asia, the gradient was nearly flat, while in Latin America, the gradient was reversed, 
with the richest least in need of contraception (Figure 1.b). Richer women were less likely to want a 
child soon, and less likely to be at risk of pregnancy, mostly because they were more likely to be 
sexually inactive (22% among the richest versus 13% among the poorest). Gradients of met need by 
wealth were seen in all settings, with the richest women having the highest met need. The gradient 
was steepest in Sub-Saharan Africa (Figure 2.b). In all regions, the gradients in private-sector 
provision of modern contraception by wealth quintile among women in need were in the same 
direction as those for overall use, but steeper. This indicates the public sector compensated to some 
degree for the inequalities in private provision, favouring the poor (Figure 3.b). The exception was 
Sub-Saharan Africa, where the overall service use and the private-sector use gradients were equally 
steep. Some of these findings have been described previously [19]. 
 
The patterns of association between wealth and need or use were echoed in the patterns seen for 
education and residence, with more privileged groups behaving in similar ways across the three 
measures of socioeconomic position. The exceptions were first, that patterns of need among all 
women by educational level were erratic in Middle East/Europe, Asia and Latin America (Figure 1.c). 
Second, that the pattern in met need was flat in Middle East/Europe and Asia by education level and 
residence (Figure 2.c and 2.d). Third, the pattern of private sector use among women in need was flat 
in Middle East/Europe by education (Figure 2.c). In all four regions, there was a steep gradient by 
privilege (greater wealth, education and urban residence) for private sector use among women using 
appropriate service types (Figure 3.b-3.d), except for the Middle East/Europe for education, where the 




Understanding the private sector: Types of methods and advice on side-effects 
Figure 5 presents the methods used by type of provider and in total (for all providers), weighted for 
country populations and unweighted. The weighted graph shows that overall, 28% of the women used 
short-acting methods, 15% injectables, 14% LARCs, and 43% permanent methods, with the high 
share of permanent methods in the weighted compared to the unweighted analysis reflecting the high 
levels of sterilisation in India and its large population. The method mix across providers appeared to 
be related to the methods’ characteristics in terms of skill-level required, the ease of training, the time 
needed to provide them, and the extent of permanence. Private retailers and non-medical providers 
from both sectors provided mainly short-acting methods. Medical providers from both sectors 
provided the widest mix of the four method types. However, a higher share of clients served by private 
medical providers received short-acting methods and injectables compared to public medical 
providers in the weighted data, while these two provider sub-types were more similar (and in a slightly 
opposite direction) in the unweighted estimates, again reflecting India’s contraceptive mix and high 
population weight. 
 
For each method type, Figure 6 shows the breakdown by provider. Short-acting methods were 
provided by the widest range of provider sub-types. However, for other methods, the more long-acting 
or permanent they were, the more likely they were to be provided by public medical providers. NGOs 
and FBOs did not contribute appreciably to the provision of any method type; private retailers, private 
specialised drug sellers and unclassifiable sources (husband, relatives/friends or other sources) were 
important providers of short-acting reversible methods, and private medical providers together with 
private specialised drug sellers provided nearly half of injectables. 
 
Figure 7 shows that in the 46-country analysis of current users of pills, injectables, IUDs, implants or 
sterilisation, 50% overall were informed of side-effects when they first obtained their method, although 
the percentages varied by method (lowest for the pill at 44% and highest for IUDs at 66%) and by 
provider sub-type. Advice on side-effects was least likely to be provided by private retailers (16%) and 
private specialised drug sellers (34%). Figure 8 further compares public medical and private medical 
providers for the five methods. It shows comparable levels of information-provision for pill, implants 
and IUDs, but some indication that public medical providers, although far from adequate, were better 
at informing women of side-effects of injectables and female sterilisation. 
 
Discussion 
This analysis of where women obtained modern contraceptives by region, wealth quintile, residence 
and educational level, with its focus on the roles of the public and private sectors, contributes to 
understanding of family-planning service provision. It goes beyond our overview paper[19] and shows 
reasons for lack of need among some women, describes inequalities in service provision by education 
and residence in addition to wealth, presents provider sub-types in both sectors, and examines quality 
by assessing method mix and side-effect advice. Strengths compared to the literature are that we: 1) 
clearly delineate who needs services, and who is using them, 2) transparently handle missing and 
unclassifiable data to indicate the implications of our assumptions, 3) use several measures of central 
tendency (weighted means and non-parametric statistics), and 4) include more countries than 
previous studies. 
 
The modern contraceptive prevalence rate (use among all women) was lowest in Sub-Saharan Africa 
(15%), while levels in the other regions were roughly comparable, with around two-fifths of women 
using modern contraceptives. The level of use among women in need was also lowest in Sub-
Saharan Africa (39%), while in the other regions ranged from 64% to 72%. These patterns are not 
new and have been reported elsewhere [11,14]. We are the only multi-country comparative study to 
examine use among women in need of services. The majority of women using modern contraceptives 
obtained them from the public sector, but private sector provision was substantial, accounting for just 
under two-fifths of provision in all regions (37%-39% across regions). 
 
Many studies note that private provision of family planning is substantial and growing, although 
definitions of the private sector vary. We found strikingly similar levels of private-sector use among 
current users in all regions, which differs from previous reports, particularly for Sub-Saharan Africa. 
Berman and Rose[20] and Zellner and colleagues[34] both observe that among modern-method 
users, private-sector sourcing was higher in Latin America than in other regions. Berman and 
7 
 
Rose[20] attribute this to the influence of the Catholic Church which makes Latin American 
governments reluctant to support family planning services, leaving non-government, private entities to 
fill the gap. Zellner and colleagues[34] describe countries with low private-sector use (3-14% of users) 
as being either in the poorest regions of the world (i.e., Sub-Saharan Africa), or transitioning from 
state-controlled to more open economies (Armenia, Kazakhstan, and Vietnam). Gwatkin et al[35] on 
the other hand, report the highest average private-sector use in the Middle East and North Africa 
region (54%), followed by Latin America and the Caribbean (51%), East Asia Pacific (41%), Sub-
Saharan Africa (35%), Asia (28%), and Europe/Central Asia (10%). Our findings could differ from 
those of others because we used population weights within regions when calculating regional 
averages, examined a different subset of countries, or excluded unclassifiable sources from our 
estimates, or because the private-sector market share actually changed over time. 
 
We examined provider sub-types in greater detail than previous studies. A previous review and 
estimate had indicated that faith-based provision is small [53]; our results concurred and also extend 
this finding to NGO provision. Considering the efforts by some donors to work outside the government 
sector, this is unexpected, but could have occurred if provider sources were misclassified, for 
example if NGOs were not strongly branded or were working through public or commercial providers 
(such as through social marketing or social franchising)[14]. The low NGO and FBO share in private-
sector provision meant that nearly all private-sector provision was from private commercial providers 
(91-97% across regions). The combination of private specialised drug sellers and private retailers 
accounted for the majority of private-sector provision in Sub-Saharan Africa, whereas in the other 
three regions, private specialised drug sellers and private medical providers played the predominant 
role.  
 
We also found that virtually all public-sector provision was medical, with community-based workers 
making a negligible contribution (≤1% of public-sector services), except possibly in Asia, where they 
provided 5% of modern contraceptives. Cleland and colleagues[14] note this previously, explaining 
that scaling-up community-based workers to achieve wide geographical coverage poses logistical 
difficulties, because large numbers of workers have to be recruited, supplied with contraceptives and 
supervised.  
 
The descriptive analyses on inequalities by socioeconomic position (Figures 4.b to 4.d) need to be 
interpreted cautiously, particularly for education. For example, as we move from Figure 1.c to 4.c, the 
sample size reduces each time, reducing the precision of our estimated proportions. This is not a 
problem per se, because the sample size in each category is sufficient to provide a reasonably 
precise estimate. However, when we look at country-level statistics, we can see that some countries 
have very few women educated to a higher level, while others have very few women with no 
education. This confounding effect means that rather than illustrating the differences in family-
planning provision across education levels, we illustrate the differences in family planning provision 
across countries with low and high levels of education. This effect is most marked in the Middle 
East/Europe region (Figure 3.c), where the chart appears to show almost no difference in private 
coverage by education levels. However, inspecting the country-level detail (not shown) revealed that 
increased education was associated with increased private provision within each country in the 
region. The discrepancy between the country picture and the regional estimate by education arises 
because only Egypt and Morocco provide significant numbers of women to the sample in the lowest 
category of education, so the estimate of private coverage is based mainly on those two countries. 
Ukraine, on the other hand, provides a large number of highly-educated women to the sample, and 
has a very low proportion of private provision. The effect does not appear to be a problem when 
stratifying by wealth quintile because relative wealth is a within-country indicator, nor does it appear to 
be a problem when stratifying by residence because of the mix of methods and proportions of 
rural/urban residents within countries. 
 
With these caveats in mind, the richest, urban, and most educated women tended to be at less risk of 
pregnancy, which decreased need, but were also less likely to want a child soon, which increased it 
(Figure 1.b-1.d). The lower need in richer women was because they were less likely to be sexually 
active than poorer women. The gradients in contraceptive use among women in need generally 
followed expected patterns of higher use and greater private-sector use among the wealthier, urban 




In the Middle East/Europe, Asia and Latin America regions, we found relatively privileged women 
used fewer public-sector, and more private-sector, services (Figures 2.b-2.d). This finding was also 
recorded by Gwatkin et al[35] and suggests that generally, public subsidies are benefitting the poor, 
despite evidence that in some settings they benefit the wealthy [19,42,54]. This relationship did not 
hold in Sub-Saharan Africa, where we found that the proportion of women in need using the public 
sector was fairly constant across socioeconomic groups. The reasons why the public-sector failed to 
favour the poor in this region may relate to high absolute levels of poverty, where the poorest cannot 
afford the direct or indirect costs of access, even to public facilities, or where even the richest may not 
have incomes that enable them to purchase private services.  
 
The optimal approach to assessing equity of use among women is to consider those who need 
contraception rather than measure the contraceptive prevalence rate among all women [21,25]. If, for 
example, richer women have more need for contraception than poorer women because they desire 
fewer children, they could well have higher use, while still having equitable met need. Apart from our 
study, all research examining equity of private-sector coverage has looked at equity of service use 
among all married women of reproductive age, rather than among those in need of services. We 
observe high levels of unmet need, even among the wealthiest women (>30% of women in need). 
There is urgent need to redress this unmet need, and in settings where population growth remains 
high, more women will need to receive services just to remain at the same modern contraceptive 
prevalence rate, and services will need to grow even more rapidly to cover unmet need, particularly if 
need for services is also increasing because of smaller desired family sizes. 
The question of whether, and how, the private sector contributes to addressing these pressures is 
discussed in the literature from three main angles. It is argued that having more providers, including 
more private providers, can first, create demand for services (i.e., by introducing new methods, 
marketing and reducing stigma) and second, improve physical access by reducing average 
distances[14,55,56]. However, the main argument revolves around the scarcity of resources and 
whether family planning should be free or subsidised for all women or only for the most economically 
vulnerable. Some authors argue that shifting wealthier women to pay for family planning from the 
private-sector could free donor or government funding to intensify efforts to reach the poorest via 
public services [33,57,58]. The latter discourse revolves largely around substitution, and not 
necessarily about increasing absolute coverage among users. 
 
Governments certainly differ in how much they (or donors) are willing or able to invest in public 
services, as well as in their views about whether national health goals and universal health coverage 
are best promoted through predominately public, or deliberately pluralistic, family planning provision, 
including via contracting out to private providers. We have empirical findings on met need and equity 
of met need by sector but cannot comment on the underlying question of the extent to which the 
patterns observed stem from deliberate policies, unintended consequences of these policies, or policy 
failures, and if so, what types of policies and what types of failures. Others who have examined the 
effects of expanding private-sector provision show variable results by country: some decreasing 
inequity (Nigeria, Uganda, Morocco and Indonesia)[21,25]; some experiencing fluctuating or 
unchanging inequity (Bangladesh, Indonesia and Ghana)[21,25]; and one (Kenya) showing increasing 
inequity in rural areas and the opposite in urban areas[25]. The purposive selection of countries with 
high and growing commercial private-sector market shares and high contraceptive prevalence rates 
(>20%) may have influenced their findings. The question on the effect of expanding private-sector 
provision on equity merits further study on a wider subset of countries, using women in need as the 
study population. In the absence of public funding, a predominance of private-sector provision may 
lead to high inequity, as documented in Paraguay[27]. However, there are also reports that targeting 
efforts are weak or ineffective, with, for example, the relatively richer benefitting from the expansion of 
government services in Egypt, or with the private-sector market share being eroded by government 
expansion in Peru[27,57].  
 
A systematic review of studies comparing all types of private and public ambulatory health care in 
low- and middle-income countries found 80 studies which indicated that many services, irrespective of 
sector, scored less than 50% on infrastructure, clinical competence, and practice. The formal private 
sector was better for drug availability, responsiveness, and effort, but differences between sectors 
were modest and the authors concluded that the view that one sector is clearly better than another 
was not supported by their review [59]. In terms of quality, we identified some evidence that reliance 
on the private sector may have meant less method choice, at least in Sub-Saharan Africa, and to a 
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lesser extent in Asia. When the poorest women sourced methods from the private sector, they were 
more likely to frequent “lower” calibre providers, with lower levels of training, and more restricted 
potential for offering a wide method choice. We cannot tell if women (or their partners) chose the 
method first and obtained it from their preferred provider, or whether their choices were constrained 
because their preferred methods and providers were not accessible, affordable, or reliably stocked. 
On the other hand, non-medical private providers most often provided condoms, which may align with 
prevention strategies in high HIV prevalence settings[14], such as in Sub-Saharan Africa, which 
accounts for nearly 70% of new HIV infections globally[60].  
 
Private-sector providers overall, and private retailers/specialised drug sellers in particular, were more 
likely to be the source of short-term methods, which have higher failure rates, and which are more 
demanding of users in terms of the need for adherence and the frequency of visits needed for 
resupply, thus posing higher time and travel costs on women. Zellner and colleagues[34] note that 
short-acting methods users (which largely overlap with our definition of “short-acting reversible” 
methods) were more likely to rely on the private sector for their methods than long-acting reversible or 
permanent contraceptive users. They hypothesised that short-acting methods may be more 
accessible in terms of proximity to a source and availability of products in the private sector than they 
are in the public sector, or that the low costs of long-acting methods in the public sector may attract 
women who could not otherwise afford to pay the private-sector prices. The high up-front costs of long 
acting/permanent methods in the private sector versus lower initial costs for short-acting methods 
may also deter women from using them. Some of these differences may stem from the nature of 
different sub-types of providers, because, for example, private retailers would be unable to provide 
LARCs or permanent methods. Health facility assessments in Tanzania, Kenya and Ghana 
comparing public to private (for-profit, NGO and FBO) facilities found that the public sector offered a 
broader method mix [40]. We compared private and public medical providers (who had similar 
qualifications and theoretically the same capacity to provide a similar method mix), and while we did 
not adjust for variations of method mix by country, we found that private medical providers were more 
likely to give injectables, and public medical providers were more likely to provide sterilisation 
(weighted). In the unweighted analysis, the method mixes of private medical and public medical 
providers were more similar.  
 
Quality was assessed by the percentage of women advised on side-effects and was found to be 
suboptimal (50% overall), although it varied by method and provider sub-type. Within public and 
private medical providers, side-effect advice was slightly higher and comparable. Health facility 
assessments in Tanzania, Kenya and Ghana determined that technical quality of family planning 
provision (assessed by clinical history, examination, appropriate injection practice and length of 
consultation) was comparable between private and public facilities, while interpersonal quality (waiting 
time, privacy and confidentiality, client concerns noted, method use explained and injectable 
prescribed) was higher in private facilities. Client satisfaction (composite of 12 elements of perception) 
was considerably higher in private facilities [40]. The restriction of this study to facilities may explain 




Our study has some limitations. Countries without DHS data were excluded, and representation of the 
Middle East/Europe and Latin America regions was low. The analyses of side-effect advice further 
excluded eleven countries which did not collect these data. The surveys asked women about current 
need and use, but some provision, particularly for long-acting methods and some of the information 
on side-effects, may have referred to a period of up to five years before the survey, and thus been 
subject to recall error. Some of the surveys included were from as early as 2000, and practices may 
have changed since then. We also draw attention to the respondents interviewed: most DHS interview 
all women of reproductive age, but some in the Middle East/Europe and Asia regions excluded never-
married women, resulting in slightly inflated estimates of proportion of women in need. 
 
Other limitations stem from using women’s self-reports and the difficulties of working with 
questionnaires from 57 surveys, where response options were variably conflated, headings were 
inconsistent, or sector of provision was unclassifiable[45]. As early as 1996, Berman and Rose 
identified the inconsistent definitions of private providers across countries as problematic [20]; 
progress has been made in response options in recent survey tools, but improvements are still 
required to standardise groupings and terminology. There are also limits to what women can 
10 
 
reasonably be expected to report, in terms of correctly classifying providers, for example, where NGO 
support is provided to private providers through franchising, or where private for-profits are hard to 
distinguish from not-for-profits, or public from FBOs. It seems necessary to validate women’s recall of 
provider type, and to give strong consideration to improving other non-survey data sources.  
 
Conclusion 
To redress nearly two decades of neglect, there is now interest in exploring a range of approaches to 
deliver family planning services and to improve their quality, including by engaging with the private 
sector. Our analysis makes an important contribution by describing the different public and private 
modalities currently contributing to family planning coverage, and by comparing their equity, method-
mix and quality of advice given on side-effects by provider type.  
 
Key findings were that Sub-Saharan Africa had the lowest levels of met need, but that there was still 
large unmet need in other regions. Moreover, all three indicators of socioeconomic position examined 
showed inequalities in met need. Among family planning users, the main source of provision was the 
public sector – and almost entirely from medical providers as opposed to community-based health 
workers. However, the private-sector’s role was substantial, accounting for just under two-fifths of 
provision in all regions, with nearly all contraceptives obtained from private commercial, as opposed 
to NGO or faith-based, providers. The share of non-medical providers (i.e., retailers) among the 
private sector was highest in Sub-Saharan Africa. By their nature, these providers are likely to offer 
the narrowest choice of methods, mainly condoms. We also found that that women using short-acting 
methods were most likely to obtain them from private-sector providers. 
 
Given the magnitude and significance of private-sector family planning provision in many countries, 
overall and even among the underprivileged, greater and more systematic efforts are needed to 
understand more about reasons why women choose the private sector, their quality of care, and how 
this can be improved. There is also a need to carefully consider and assess the potential impact of the 
relative attention focused on public versus private sectors on equity. The largest potential market for 
family planning is among the poor, where there is the greatest unmet need, while private sector 
services are generally more used by the rich. Both high levels of unmet need and the richest opting 
for more private use, suggest public services are not meeting at least some aspects users’ 
expectations with respect to convenience, quality or cost. A better understanding of the supply and 
use of private services, and the impact of private-sector focused interventions, will help governments 
assess whether national health goals and universal health coverage are best promoted through 
predominately public, or deliberately pluralistic, family planning provision and how best to balance 

































































































































































Table 1. Classification of sources of family planning provision among women in need by appropriateness of the service type and by sector, with 
examples
†
 of DHS response options 
Classification Definitions and Examples 
Did not use any service 
(unmet need) 
Did not use any method but did not want a child in the next two years 
Did not use an appropriate 
service type (unmet need) 
Used a traditional method such as withdrawal, abstinence, and folkloric methods (i.e., use of herbs), lactational 
amenorrhea method (LAM), or fertility awareness methods  
Used an appropriate service 
type 
Used a modern contraceptive method  
Permanent: female or male sterilisation 
Long-acting Reversible: implants, intrauterine devices  
Injectables: Depo-Provera and other injectables 
Short-acting Reversible: male and female condoms, diaphragm, foam/jelly, oral contraceptive pills, emergency 
contraception 
 
Used an appropriate service 
type; classifiable sector of 
provision 
Used modern contraception and reported a service location other than husband/ friend/ relatives, other providers, 




Service location: All government/ public service locations  
Public medical: Public hospital, polyclinic, health center, family doctor, women’s health centers, family planning 
clinics, government pharmacy 




Service location: All private providers  
Private medical: Private hospital/clinic, private doctor, private nurse/midwife, private health center 
Private specialised drug seller: Private pharmacy, private drug store, private dispensary 
Private retailer: Shop/market, bar/disco, vending machine 
Faith-based (FBO): Mission hospital, health center, mobile clinic, dispensary 
NGO: NGO health facility, mobile clinic, NGO field worker 
Used an appropriate service 
type; sector of provision not 
classifiable 
Used a modern method and reported a missing source location or obtained a method from husband/ friend/ 
relatives/providers abroad 
Missing location of source 
Unclassifiable locations (sector not known): Husband, friend/relative, peer educators, support group, school, 
hospital/clinic abroad, missing source 
†
 There were 141 unique family planning provider response options across the 57 surveys, so only examples are shown. 
Table 2. Geographic regions and percentage of their populations covered by the DHS surveys included 
in the analysis 








% of population of 
region covered by 
DHS surveys
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 UN Population Estimates, 2008. 
2 
Assuming DHS are nationally representative for each country. 
Table 3. Summary of need, use, and sector of use for family planning services across regions (including 




















Not using any method, missing need status <1 <1 1 <1 1 0 (0-6) 
Not using any method, not at risk of pregnancy  35 26 27 34 29 33 (11-52) 
Not using any method, wants a child 26 11 14 6 16 13 (5-50) 
Unmet need for family planning (not using any 
method or using traditional methods) 
24 23 19 17 20 24 (11-49) 
Use of appropriate family planning methods 15 40 39 43 34 23 (2-57) 
TOTAL 100 100 100 100 100  
Selected categories  
Need for family planning  39 63 58 60 54 50 (24-80) 
Using public-sector service 9 25 23 25 20 13 (1-46) 
Using private-sector service 5 14 14 16 12 8 (1-39) 
Women in need 
Unmet need for family planning (not using any 
method or using traditional methods) 
61 36 33 28 37 54 (16-94) 
Use of appropriate family planning methods 39 64 67 72 63 46 (6-84) 
TOTAL 100 100 100 100 100  
Selected categories 
Using public sector service 22 39 40 42 37 28 (3-58) 
Using private sector service 14 23 24 27 22 16 (2-55) 
Using unclassifiable sector (husband, relatives, 
friends or other source) or missing location of 
service 
3 2 3 2 3 2 (0-12) 
Women using appropriate service type  
Using public sector service 57 61 60 59 60 56 (15-92) 
Using private sector service 35 36 35 38 35 38 (6-72) 
Using unclassifiable sector (husband, relatives, 
friends or other source) or missing location of 
service  
8 3 5 3 5 4 (0-28) 
TOTAL 100 100 100 100 100  
Women using appropriate services with a classifiable sector 
Using public sector service 62 63 63 61 63 59 (20-94) 
Using private sector service 38 37 37 39 37 41 (6-80) 
TOTAL 100 100 100 100 100  
Women using public sector services 
Public medical 99 100 95 100 96 100 (48-100) 
Public non-medical 1 <1 5 <1 4 0 (0-52) 
TOTAL 100 100 100 100 100  
Women using private sector services 
Private medical 30 41 60 45 54 23 (3-84) 
Private specialised drug seller 47 52 31 48 36 43 (0-97) 
Private retailer 14 4 5 3 6 6 (0-85) 
Faith-based (FBO) 6 1 1 0 1 0 (0-36) 
NGO 3 2 3 4 3 0 (0-38) 
TOTAL 100 100 100 100 100  
Combined categories 
Private commercial 91 97 96 96 96 99 (27-100) 
Private non-commercial 9 3 4 4 4 1 (0-73) 
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Sub-Saharan Africa Middle East/Europe Asia Latin America
Proportions of private sector users, by source, region and residence
3.c 3.d 
4.c 4.d 
Figure 5.Distribution of methods by provider type  





















































































































































































































































































































Private specialized drug 
seller
Private medical
Figure 7. Percentage of women who were told about side effects by the first source of current modern FP method 
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Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
Bulatao et al[1] 1993 
 
DHS, Bangladesh CPS, Honduras Epidemiology& 
Family Health Survey: 30 countries in sub-
Saharan Africa; North Africa; Asia; Latin America/ 
Caribbean 
1985-1991 
Unweighted regional averages constructed 
Married women reproductive age 
Public: not defined  
Pharmacies & shops: commercial outlets 
Private practitioners: private practitioner, 
clinic, hospital (including employer-supported 
services) 
Voluntary: NGOs (private voluntary 
organizations & various donor-funded 
agencies), private universities, contractors 
 
None Sector of modern contraceptive use among users: modern not defined 
Unweighted Mean (Range) 
Pharmacies and shops:  
Sub-Saharan Africa: 15% (1–38%) North Africa: 25% (9–53%) Asia: 9% (2-18%) 
Latin America/Caribbean: 19% (2–48%) 
 
Private practitioners: 
Sub-Saharan Africa: 11% (2–38%); North Africa: 13% (9–20%); Asia: 10% (3– 0%); 
Latin America/Caribbean: 23% (4–54%) 
 
Voluntary organizations: 
Sub-Saharan Africa: 15% (0-49%); North Africa: 0% (0–1%); Asia: 2% (0–5%); Latin 
America/Caribbean: 15% (0–52%) 
Ayad et al[2] 1994 
 
DHS: 25 countries in Asia; Near East/ North Africa; 
sub-Saharan Africa; Latin America/ Caribbean 
1986-1990 
Individual countries –overall averages not 
constructed 
Married women or women in consensual union  
15-49 (15-44 in Guatemala & Brazil) 
Government stationary: government-run in 
fixed location 
Government mobile: government outreach 
workers, mobile units 
Pharmacy: privately owned sources 
Other private: NGOs, private doctors, 
private clinics, other medical providers 





Private for-profit: private doctor, private 
hospital, private clinic, pharmacy, market, 
shop 
NGO: IPPF and church institutions 
Public: government, parastatal 




Source of information on periodic 
abstinence 
Public: government, parastatal 
Private: private doctor, private hospital or 
clinic, pharmacy, NGO 
Church: Protestant missions, Catholic 
churches 










Sector of modern contraceptive use among users: modern not defined 
Pharmacy: Sub-Saharan Africa: 1-23%; Near East/North Africa: 10-46%; Asia: 3-
7%; Latin America/Caribbean: 5-46%  
Other private: Sub-Saharan Africa: 2-52%; Near East/North Africa: 9-26%; Asia: 8-
10%; Latin America/Caribbean: 14-56%  
 
Sector of modern clinical methods among users: defined as IUD, Norplant, male 
& female sterilisation 
Pharmacy and Other private (pharmacy ranges from 0-1% in all countries): Sub-
Saharan Africa: 11-40%; Near East/North Africa: 8-53%; Asia: 6-9%; Latin 
America/Caribbean: 20-78%  
 
Sector of modern supply methods among users: defined as pill, injections 
condom, vaginal methods (diaphragm, sponge, foam, jelly) 
Pharmacy: Sub-Saharan Africa: 1-32%; Near East/North Africa: 12-89%; Asia: 4-
16%; Latin America/Caribbean: 20-92%  
Other private: Sub-Saharan Africa: 4-58%; Near East/North Africa: 1-12%; Asia: 7-
18%; Latin America/Caribbean: 2-48%  
 
Sector of individual contraceptive methods among users: pill, IUD, female 




Sub-Saharan Africa: Pharmacies: 1-29%; Other private: 4-59%; Near East/North 
Africa: Pharmacies: 11-88%; Other private: 1-8%; Asia:  
Pharmacies: 2-21%; Other private: 3-13%; Latin America/Caribbean:  
Pharmacies: 11-92%; Other private: 2-51%. 
IUD: Other private: Sub-Saharan Africa: 10-72%; Near East/North Africa: 11-56%; 
Asia: 3-10%; Latin America/Caribbean: 0-89%. Pharmacy 0% except in Latin 
America/Caribbean (0-3%). 





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
Africa: 2-28%; Asia: 3-8% Latin America/Caribbean: 21-88%. Pharmacy 0% in all 
countries except Egypt (<2%). 
 
Equity of sector of modern contraceptive use among users: Urban users and 
those with secondary education or higher were more likely to obtain their methods 
from the private sector compared to their rural counterparts. 
World Bank[3] 1994 
 
DHS, Honduras Epidemiology& Family Health 
Survey: 15 countries (Dominican Republic, Egypt, 
El Salvador, Honduras, Indonesia, Sri Lanka, 
Thailand, Zimbabwe) (Botswana Brazil, Colombia, 
Ecuador, Mexico, Trinidad &Tobago, Tunisia)  
Countries with CPR >30% 
1985-1991 
Averages constructed for countries with per capita 
income <$1000 per year and 
 >$1000–not stated how 
Married women reproductive age  
Public: not defined  
Private commercial: not defined 










Sector of modern contraceptive use among users: modern not defined 
Average (Range) 
Countries with per capita income below $1,000 per year 
Private commercial sector: 25% (3–73%); Private voluntary sector: 9% (0–52%)  
  
Countries with per capita income above $1,000 per year: 
Private sector provision: 37% (5–69%); Private voluntary sector: 9% (0–32%) 
 
Equity of sector of modern contraceptive use among users: 
In Colombia, government plays a much greater role in the provision of services to 
users with little or no education and in rural areas; within-country differences in 
educational background are found between users of government and commercial 
sources of family planning in Egypt. Jamaica, Morocco. Sri Lanka, and Thailand. 
(data not shown) 
Berman & Rose[4] 1996 
DHS: 11 countries in Asia/ Near East; Africa; Latin 
America/ Caribbean (Bolivia, Colombia, Guatemala, 
Paraguay, Botswana, Kenya, Sudan, Uganda, 
Indonesia, Morocco, Tunisia) 
1987-1991 
Individual countries –overall averages not 
constructed 
Not currently pregnant women who were ever-
married (8 countries) or currently-married (3 
countries) 
15-49 (Guatemala 15-44) 
Public: not defined 
Private: pharmacies(unless otherwise 
specified in survey) 
Other: traditional providers, schools, 
churches, family & friends, others  
 












working or not 
working 
Sector of modern contraceptive use among users: modern not defined 
Overall, Latin American countries dominated in private provision of FP services, 
ranging from 61.9% (Guatemala) to 83.7% (Paraguay). Mean private sector 
provision in Latin America was 70%, in Africa 29% and in Asia 22%, and across all 
countries was 42%. 
 
Equity of sector of modern contraceptive use among users:  
Women’s education, employment status and urban residence had positive effects on 
the probability of private provider use. There was no systematic link across countries 
between private sector use and type of contraceptive provided. 
Curtis & Neitzel[5] 1996 
DHS: 22 countries in Asia/ Near East/ North Africa; 
sub-Saharan Africa; Latin America/ Caribbean 
1990-1993 
Individual countries –overall averages not 
constructed 
Married women or women in consensual union  
 15-49 
Government stationary: government-run in 
fixed location 
Government mobile: government outreach 
workers, mobile units 
Pharmacy: privately owned pharmacy, drug 
store 
Other private: NGOs, private doctors, 
private clinics, other medical providers 
Other sources: family, friends, church, 










Sector of modern contraceptive use among users: modern defined as pill, IUD, 
Norplant, injectables, diaphragm, foams, jellies (vaginal methods), condom, female 
& male sterilisation, periodic abstinence: if >1, more effective method chosen in 
following order: IUD, condom/ vaginal methods, spermicide, periodic abstinence, 
withdrawal. 
Pharmacy: Sub-Saharan Africa: <1-36%; Asia: 2-31%; Latin America/Caribbean: 13-
47%. 
Other private: Sub-Saharan Africa: <1-54; Asia: 6%-60%; Latin America/Caribbean: 
18-52%. 
 
Sector of modern clinical methods among users: defined as IUD, Norplant, male 





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
Pharmacy: Sub-Saharan Africa: <1%; Asia: <1%; Latin America/Caribbean: <1%. 
Other private: Sub-Saharan Africa: 0-54%; Asia: 15-70%; Latin America/Caribbean: 
23-68%. 
 
Sector of modern supply methods among users: defined as pill, injections 
condom, vaginal methods 
Pharmacy: Sub-Saharan Africa: 0-56%; Asia: 3-81%; Latin America/Caribbean: 50-
79%. 
Other private: Sub-Saharan Africa: 0-60% Asia: 3-25%; Latin America/Caribbean: 5-
13%. 
 
Sector of individual contraceptive methods among users 
Pill:  
Pharmacy: Sub-Saharan Africa: 0-59%; Asia: 2-84%; Latin America/Caribbean: 47-
80%. 
Other private: Sub-Saharan Africa: 0-65%; Asia: 2-25%; Latin America/Caribbean: 
5-14% 
IUD: 
Pharmacy: Sub-Saharan Africa: 0-1%; Asia: 0-1%; Latin America/Caribbean: 0-8%. 
Other private: Sub-Saharan Africa: 4-77%; Asia: 16-85%; Latin America/Caribbean: 
39-78%. 
Female sterilisation: 
Pharmacy: Sub-Saharan Africa: 0%; Asia: 0%; Latin America/Caribbean: 0-1%. 
Other private: Sub-Saharan Africa: 0-57%; Asia: 13-35%; Latin America/Caribbean: 
23-77%. 
 
Equity of sector of modern contraceptive use among users:  
Residence:  
In 6/11 countries in Sub-Saharan Africa, 6/6 countries in Asia, and 4/5 countries in 
Latin America/Caribbean, urban users were more likely to obtain their methods from 




In 7/11 Sub-Saharan African, 4/6 Asian, and 4/5 Latin American/Caribbean 
countries, users with a secondary or higher education were more likely to obtain 
their methods from the private sector (pharmacy and other private combined) 
compared to users with no education.  
Hanson et al[6]2001 
DHS, Honduras Epidemiology & Family Health 
Survey: 
15 countries (Dominican Republic, Egypt, El 
Salvador, Honduras, Indonesia, Sri Lanka, 
Thailand, Zimbabwe) (Botswana Brazil, Colombia, 
Ecuador, Mexico, Trinidad &Tobago, Tunisia)  
Countries with CPR >30%  
Public: not defined  None Sector of modern contraceptive use among users: modern not defined. Looking 
at public sector share of contraception. 
 
Public provision of contraception in countries with a CPR of over 30% varied from 
19% (Honduras) to 94% (Botswana). Among low-income countries (<$1000 per 
capita), Honduras, Egypt, the Dominican Republic, Indonesia, El Salvador and 
Thailand, CPR and public provision of contraception were positively associated. Sri 





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
1985-1991 
Individual countries –overall averages not 
constructed 
Married women reproductive age 
capita), Brazil, Colombia, Trinidad and Tobago, Ecuador, Mexico, Tunisia and 
Botswana, CPR was negatively and significantly associated with public sector share 
of contraception. 
CDC & ORC Macro[7]2003 
RHS & DHS: 12 countries in 
Eastern Europe & Eurasia (Armenia, Azerbaijan, 
Czech Republic, Georgia, Kazakhstan, Kyrgyz 
Republic, Moldova, Romania, Russia, 
Turkmenistan, Ukraine, Uzbekistan)  
16 surveys 
1993-2001 
Individual countries -overall averages not 
constructed 
Married women or women in consensual union  
15-44  
Public medical sector: maternity hospitals, 
gynaecologic wards, women’s consultation 
clinics, polyclinics, village hospitals, 
dispensaries  
Private clinic/office: private clinics, NGOs  
Commercial sales: pharmacies  
Other: partners, friends, relatives 
Not by sectors  Sector of modern contraceptive use among users: modern defined as pill, IUD, 
condom, sterilisation, injectables, spermicides, diaphragm  
Public medical 32-95%; Private clinic/office 0-8%; Commercial sales 4-59%; Other 
0-11% 
 
Sector of individual contraceptive methods among users: 
Pill  
Public medical 12-75%; Private clinic/office 0-7%; Commercial sales 17-86%; Other 
0-12% 
Condom  
Public medical 0-26%; Private clinic/office 0-8%; Commercial sales 60-98%; Other 
2-29% 
IUD 
Public medical 61-99%; Private clinic/office 0-28%; Commercial sales 0-19%; Other 
0-4% 
Taylor et al[8] 2004 
DHS & RHS: 9 countries in Latin America/ 
Caribbean 
(Bolivia, Dominican Republic, Ecuador, El Salvador, 
Guatemala, Honduras, Nicaragua, Paraguay, Peru) 
2 surveys per country 
Time trends 
1989-1996 & 1998-2004 
Individual countries -overall averages not 
constructed 
Married women or women in consensual union  
15-49  
Ministry of Health 




For those covered by social security 
Ministry of Health: clinic, hospital or 
program 
Social security institute: system clinics, 
hospital or program 
Commercial pharmacy 
Other: private sector clinic or hospital, 
NGO, community promoter, other 
Ministry of Health 
sector by:  
Wealth quintiles  
 
Sector of modern contraceptive use among users: modern not defined 
Ministry of Health share increased between the two surveys in all countries except 
Ecuador, ranging from 25-68% across countries on the more recent survey. Private 
sector share ranged from 19%-61% on the more recent survey; having declined in 
all countries except Paraguay and Ecuador. Among users covered by social 
security, commercial pharmacy provision of methods ranged from 4% (El Salvador) 
to 51% (Paraguay), and other provision from 16% (Peru) to 47% (Honduras). 
 
Equity of sector of modern contraceptive use among users of Ministry of 
Health services: 
In 7 countries assessed, between 20-50% of users of methods from Ministry of 
Health sources were from the wealthiest two quintiles. 
Sharma et al[9] 2005 
DHS or RHS: 9 countries in Latin America/ 
Caribbean (Bolivia, Dominican Republic, Ecuador, 
El Salvador, Guatemala, Honduras, Nicaragua, 
Paraguay, Peru) 
2 surveys per country 
Time-trends 
1989-1996 & 1998-2004 
Individual countries -overall averages not 
constructed 
Married women or women in consensual union  
15-49 





Other: not defined 
Sectors by (Peru 
only):  
Wealth quintiles  
 
Sector of modern contraceptive use among users: modern defined as oral 
contraceptives, injectables, IUD, condoms, male & female sterilisations 
Private sector range 19-74%. Trend decreasing over time in 7/9 countries.  
 
Equity of sector of modern contraceptive use among users 
In Peru, following a free condom policy, contraceptive coverage increased but the 
non-MoH sector share fell from 41% to 31% (private clinic/hospitals, commercial 
pharmacies, NGO from 29% to 19%) between 1992 and 2000. Declines in non-MoH 
sector by wealth quintile ranges from 4% -17% and were biggest in the middle 
quintile.  
Zellner et al[10]2005 
DHS & RHS: 46 countries in Sub-Saharan Africa; 
Private: for-profit & not-for-profit (private 
practitioners, clinics, hospitals, laboratories, 
Private sector by: 
Wealth quintiles: 






Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
North Africa/ West Asia/ Europe; South Central/ 
Southeast/ East Asia; Latin America/ Caribbean 
1999-2005 
Individual countries -overall averages not 
constructed 
Married women or women in consensual union  
15-49 
diagnostic facilities, NGOs, FBOs, 
shopkeepers, traditional healers, 
pharmacies, pharmaceutical wholesalers, 
distributors, manufacturers)  
 
two bottom wealth 
quintiles 
combined; middle 




Public sector by: 
Richest current 
users 
Private sector: Sub-Saharan Africa: 6-51%; North Africa/West Asia/Europe: 3-49%; 
South Central/Southeast/East Asia: 11-39%; Latin America/Caribbean: 17-67%. 
 
Sector of long-acting & permanent methods among users: methods defined as 
IUD, female & male sterilisation, implants 
Private sector: Sub-Saharan Africa: 8-56%; North Africa/West Asia/Europe: 14-43%; 
South Central/Southeast/East Asia: 5-67%; Latin America/Caribbean: 15-57%. 
 
Sector of short-acting methods among users: methods defined as oral 
contraceptives; injectables; female & male condoms; diaphragm; foams, jellies, & 
other vaginal methods). Non-purchased methods such as fertility awareness-based 
methods excluded. 
Private sector: Sub-Saharan Africa: 8-65%; North Africa/West Asia/Europe: 5-66%; 
South Central/Southeast/East Asia: 20-78%; Latin America/Caribbean: 17-87%. 
 
Equity of sector of modern contraceptive use among users 
The proportion of users obtaining modern methods from the private sector by wealth 
quintile: Sub-Saharan Africa: Poorest/Poorer: 14-52%, Richest: 14-61%. North 
Africa/West Asia/Europe: Poorest/Poorer: 26-39%, Richest: 40-46%. South 
Central/Southeast/East Asia: Poorest/Poorer: 7-62%, Richest: 12-73%. Latin 
America/Caribbean: Poorest/Poorer: 5-57%, Richest: 41-76%. 
Gwatkin et al[11]2007 
DHS: 56 countries in East Asia/ Pacific; Europe/ 
Central Asia; Latin America/ Caribbean; Middle 
East/ North Africa; South Asia; sub-Saharan Africa  
Multiple surveys per country (95 surveys) 
1991-2004 
Regional and total averages - unweighted 
Married women or women in consensual union  
15-49  
Men 
Public facility: government hospitals, health 
centres, health posts, dispensaries; facilities 
operated by government-affiliated social 
securing programs 
Private facilities: private hospitals or 
clinics, private doctors’ offices, facilities 
operated by other private medical providers 
(such as NGOs) as defined in the country 
concerned; private pharmacies or shops  









Sector of modern contraceptive use among users (women): modern defined as 
male & female sterilisation, oral contraceptive pill, injectables, intrauterine device, 
male & female condom, diaphragm, cervical cap, contraceptive jelly or foam, 
implant, or some country-specific modern methods. 
Proportion of users obtaining methods from private sector by region:  
All regions: 36%; East Asia/Pacific: 41%; Europe/Central Asia: 10%; Latin America/ 
Caribbean: 51%; Middle East/North Africa: 54%; South Asia: 28%; Sub- Saharan 
Africa: 35%.  
 
Sector of modern contraceptive use among users (men): modern defined as 
above. 
Proportion of users obtaining methods from private sector - only available for Brazil 
(1996): 51%. 
 
Equity of sector of modern contraceptive use among users 
Private sector by wealth quintile: (low/high ratio, low-high difference, concentration 
index) 
All regions: 0.608, 17.804, 0.17672 
East Asia/Pacific: 0.641, 18.995, 0.15519;  
Europe/Central Asia: 0.564, 6.383, 0.17844;  
Latin America/Caribbean: 0.511, 31.782, 0.15452;  
Middle East/North Africa: 0.571, 29.004, 0.09202;  
South Asia: 0.265, 34.002, 0.27843;  
Sub-Saharan Africa: 0.726, 11.343, 0.18394.  





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
Khan et al[12] 2007 
DHS: 35 countries in sub-Saharan Africa; North 
Africa/West Asia/Europe; South/ Southeast Asia; 
Latin America/Caribbean 
Multiple surveys per country (97 surveys) 
Time-trends 
1987-2005 
Individual countries –overall averages not 
constructed 
Married women or women in consensual union  
15-49 
Public sector: not defined 
Private medical sector: not defined 
NGOs 
Other: not defined  
Country-specific definitions of these sources 
are maintained to facilitate analysis  
 
For trend analysis, private pharmacy comes 
as Other or Private medical depending on 
survey; Field workers come as Other or 
Government/public depending on survey, 
Other and NGOs are pooled 
Private medical 
sector by: 










Sector of modern contraceptive use among users: modern defined as female & 
male sterilisation, pill, IUD, injectables, implants (such as Norplant), female & male 
condom, emergency contraception, diaphragm, foam/jelly. Excluded: lactational 
amenorrhea method (LAM). In case of concurrent method use, source of the most 
effective method is used  
 
Proportions obtaining methods from the private sector: (Region: mean; range) 
Private medical sector: Sub-Saharan Africa: 7–57%; North Africa/Middle East: 3–
66%; South/Southeast Asia: 7–63%; Latin America/Caribbean: 15–55% 
NGOs: Sub-Saharan Africa: 0-12%; North Africa/Middle East: 0-3%; 
South/Southeast Asia: 0-8%; Latin America/Caribbean: 0-36% 
 
Equity of sector of modern contraceptive use among users: 
In general, urban women, more-educated women, women in wealthier households 
were more likely to use a private medical source, except Malawi, where rural women 
are more likely than urban women to use a private medical source.  
 
Trends among users of modern contraceptive methods.  
In sub-Saharan Africa, the percent using the non-public sector increased in about 
half of the countries and stayed the same or decreased in the rest. The percentage 
increased in most countries in South/Southeast Asia, but decreased in most 
countries in Latin America and the Caribbean, and in North Africa/West 
Asia/Europe. 
Stupp et al[13]2007 
RHS: 4 countries in Central America (El Salvador, 
Honduras, Guatemala, Nicaragua)  
3 surveys per country 
Time trends 
1987-1993 1995-1998 2001-2002 
Individual countries –overall averages not 
constructed 
Married women or women in consensual union 
15-49 (15-44 Guatemala) 
Ministry of Health 
Social Security: (except Nicaragua with 
MoH) 
Family planning association 
Private: private provider, private clinic, 
pharmacies 
Other: not defined 
Don’t know 
Sectors by: 
Wealth quintiles  
Sector of modern contraceptive use among users: modern defined as female 
sterilisation, injectables, orals, intrauterine devices (IUDs), condoms, vaginal 
methods, vasectomy, Norplant 
Between 1987-2002, percent of users who obtaining methods from private clinics 
decreased in El Salvador from 4% to 2%, in Guatemala from 18% to 14%, in 
Honduras from 21% to 12%, and in Nicaragua from 12% to 11%. The percent of 
users who obtained methods from pharmacies changed in El Salvador from 9% to 
5%, in Guatemala from 7% to 11%, in Honduras from 13% to 11%, and in Nicaragua 
from 17% to 12%.  
 
Equity of sector of modern contraceptive use among users:  
On the most recent survey in each country, wealthier users were more likely to 
obtain methods from private sector providers. Among the wealthiest quintile, private 
sector use ranged from 10-45% across the countries. In the poorest quintiles, 
private sector use ranged from <5% to 11% across the countries. 
Agha & Do[14]2008  
DHS: 5 countries in Africa; Asia (Morocco, 
Indonesia, Kenya, Ghana, Bangladesh) 
Modern CPR>20% & commercial sector share> 
30%, 3+ surveys per country, & growing share of 
commercial sector  
1987-2004  
Individual countries –overall averages not 
Public: government hospitals/clinics, 
government health centres 
Private: private hospitals/clinics, private 
doctors, pharmacies, shops/stores 
NGO/other: NGOs, friends/relatives 
 




DHS rounds in 
each country 
used. 
Sector of modern contraceptive use among users: modern not defined 
From the earliest to the most recent included survey, the percentage of users 
obtaining methods from the private sector changed in Morocco (20-40%), Indonesia 
(12-65%), Kenya (9-32%), Ghana (25-42%) and Bangladesh (15-34%). 
 
Equity of sector of modern contraceptive use among users 
From the earliest to the most recent included survey, the percentages of users 





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
constructed 
Married women or women in consensual union 
15-49  
39%) and the richest quintile (23-64%), in Indonesia the poorest (3-31%) and the 
richest quintile (52-75%), in Kenya the poorest (6-15%) and the richest quintile (22-
46%), in Ghana the poorest (25-31%) and the richest quintile (25-47%), and in 
Bangladesh the poorest (5-35%) and the richest quintile (18-57%). 
Limwattananon[15]2008 
DHS: 25 countries in sub-Saharan Africa; South/ 
Southeast Asia 
Multiple surveys; 2 most recent 1995-2000 & 
2001-2006  
Individual countries –overall averages not 
constructed 
Married women or women in consensual union 
15-49  
Public: government hospital/ clinic, 
government field worker, family welfare 
centre  
Formal Private: private hospital/ clinic, 
doctor, pharmacy, NGO clinic, depot holder, 
fieldworker  








Sector of modern contraceptive use among users: modern not defined 
Private sector provision 3-70%. In 10/21 countries in sub-Saharan Africa and 
South/Southeast Asia over 50% obtained methods from the private sector. Private 
formal and informal sector: Sub-Saharan Africa: 20-79%; South/Southeast Asia: 15-
72%.  
 
Equity of sector of modern contraceptive use among users 
7/20 countries had a urban rural gap of more than 20% in private sector use, with 
urban women using more private in all cases.  
7/20 had a richest-poorest quintile gap of >20%, with the richest using more private 
contrasted to the poorest in 18 countries. In the other two, Mozambique and Mali, 
both the public and private sectors were more used by the richest. 
 
Trends 
Between the DHS surveys, the formal private sector share for Cameroon, Malawi 
and Cambodia decreased by >10%, while Indonesia’s formal private sector share 
increased by 22%. During the same period, the informal private sector share 
changed by more than 10%, increasing in Cameroon, Cambodia and Malawi (25%), 
but decreasing in Uganda.  
Hotchkiss et al [16]2011 
DHS: 4 countries (Nigeria, Uganda, Bangladesh, 
Indonesia)  
3+ rounds & an expansion in private commercial 
sector (excluding NGOs) 
1987-2008 
Individual countries –overall averages not 
constructed 
Married women or women in consensual union 
15-49 
Government sector: not defined 
Private commercial sector: commercial 
outlets including chemists, shops, 
pharmacies, traditional healer/ doctor, 
midwife, & private health care facilities & 
workers  
Other sources: NGOs, faith-based 







Sector of modern contraceptive use among users: modern defined as male 
condoms, pills, IUDs, injectables, diaphragm, foam, jelly, sterilisation, and implant. 
Lactational amenorrhea method (LAM) was not classified as a modern method. 
Between the earliest survey (1987-1999) and the most recent (2006-2008), the 
proportion of users obtaining methods from the private sector increased in all four 
countries, and ranged from 40-70% in the most recent survey rounds. 
 
Equity of sector of modern contraceptive use among users  
The proportion of users from the poorest wealth quintile who used private sector 
sources increased over time in each country. At the most recent survey (2006-
2008), more than half relied on the private sector for FP provision in Indonesia and 
Nigeria, with about a third and a quarter relying on the private sector in Uganda and 
Bangladesh, respectively. 
Nguyen et al[17]2011 
DHS: 6 countries in Sub-Saharan Africa (Ethiopia, 
Kenya, Malawi, Rwanda, Tanzania, Uganda) 
1999-2006 
Individual countries –overall averages not 
constructed 
Women using modern contraception  
15-49 
Public: not defined 
Private for-profit (facilities): hospital and 
clinics 
Private for-profit (pharmacies): 
pharmacies, drug vendors, shops  
Private not-for-profit: not defined 
Other: not defined 
None Sector of modern contraceptive use among users: modern not defined  
In all countries except Uganda, the public sector played a larger role than the private 
sector in the provision of FP services (ranging between 53-80% of users). 58% of 
users in Uganda obtained methods in the private sector. Within the private sector, 
private facilities dominated the market for the pill and IUDs, while pharmacies and 
drug vendors provided the majority of condoms. Private sector share of the oral pill 
ranged from 6% (Malawi) to 55% (Uganda) for private facilities, and 1% (Malawi) to 
23% (Kenya) for pharmacies and drug vendors; for IUDs from 7% (Malawi) to 47% 
(Uganda) for private facilities; and for condoms from 0.7% (Rwanda 2005) to 20 





Population and recall period  
Sector definitions Equity analysis Measure of Family Planning and Results 
pharmacies and drug vendors. 
Chapman et al[18]2012 
DHS: 11 countries in sub-Saharan Africa  
2 surveys per country, both men & women 
surveyed in same year and a PSI program  
1998-2007 
Individual countries –overall averages not 
constructed 
Men and women with a non-married, non-
cohabiting partner 
Men: 15-24 
Women: Not stated 
Public: government hospital, government 
health centre, family planning clinic, mobile 
clinic, other public, rural health centre 
Private: private hospital, private doctor, 
other private, mission facility, other retail 
Pharmacy 
Shop: gas station or general shop 
Friends or family 
Other: bars, clubs, church 
Not by sectors Sector of condoms among users at last sex with their non-marital, non-
cohabiting partner 
Female users 
Private sector: 1-16% (first survey); 0-16% (second survey)  
Pharmacy: 0-27% (first survey); 0-26% (second survey). 
Shop: 21-73%(first survey); 31-67%(second survey)  
Other (bars, clubs, church):0-3% (first survey); 0-19%(second survey)  
Male users 
Private sector provision: <1-18% (first survey); 0-12% (second survey).  
Pharmacy provision: <1-37% (first survey); <1-14% (second survey).  
Shop: 9-83% (first survey); 40-71%(second survey)  
Other (bars, clubs, church): 0-8% (first survey); 0-37% (second survey) 
Ross & Agwanda[19]2012 
DHS & UNDP: 38 countries in sub-Saharan Africa 
Multiple surveys per country (95 surveys)  
1980-2008  
Individual countries –overall averages not 
constructed 
Married women or women in consensual union  
using injectables 
15-49 
Public: not defined 
Non-public: private medical sector and 
pharmacies 
None Sector of injectables among users 
The public sector was the primary source of injectables. In the East/South region, 
the percentage of users obtaining injectables from public sector ranged from 56-
96% in the earlier and from 36-95% in the more recent survey. In the West/Central 
region, percentage of users obtaining injectables from public sector ranged from 32-
98% in the earlier and from 54-97% in the more recent survey.  
Wang et al[20] 2012 
DHS & SPA: 4 countries (Tanzania, Kenya, 
Rwanda, Uganda)  
5 surveys 
2003-2010 
Individual countries –overall averages not 
constructed 
Currently married women  
15-49 
Public: public hospital, public health centre, 
public clinic/ dispensary, other public 
Private: private hospital/clinics, private 
pharmacy, other private 




Not by sectors  Sector of modern contraceptive use among (excluding condoms) users: 
Proportion of users obtaining methods from private sector varied from  
Kenya (37% on more recent survey), Rwanda (6%), Uganda (54%) and Tanzania 
(20%), and private hospitals/clinics were the predominant type of private provider. 
 
Sector of individual contraceptive methods among users 
Injectables: 
Proportion of users obtaining injectables from private sector ranged from 4% in 
Rwanda to 59% in Uganda. 
 
Pill:  
Proportion of users obtaining pills from private sector ranged from 8% in Rwanda to 
70% in Uganda. 
 
Condom: 
Proportion of users obtaining condoms from private sector ranged from 16% in 





































Web Table 2: List of countries included in the analyses of family planning by survey year, characteristics of 
women sampled and whether data were collected on whether women were advised about side-effects 










Benin  2006  all  
Burkina Faso  2010  all  
Burundi  2010  all  
Cameroon  2011  all  
Chad  2004  all No 
Republic of the Congo 2005  all No 
Dem. Republic of Congo  2007  all  
Ethiopia  2011  all No 
Gabon  2012  all  
Ghana  2008  all No 
Guinea  2005  all  
Kenya  2008‐9  all  
Lesotho  2009  all  
Liberia  2007  all No 
Madagascar  2008‐9  all  
Malawi  2010  all  
Mali  2006  all  
Mozambique  2011  all  
Namibia  2006‐7  all  
Niger  2006  all  
Nigeria  2008  all  
Rwanda  2010  all  
Sao Tome & Principe 2008‐9  all  
Senegal  2010‐11  all  
Sierra Leone  2008  all  
Swaziland  2006‐7  all No 
Tanzania  2010  all  
Uganda  2011  all  
Zambia  2007  all  
































Albania  2008‐9  all  
Armenia  2010  all  
Azerbaijan  2006  all  
Egypt  2008  ever‐married  
Jordan  2007  ever‐married  
Moldova  2005  all  
Morocco  2003‐4  all  
Turkey  2003  ever‐married No 


















Bangladesh  2011  ever‐married No 
Cambodia  2010  all  
India  2005‐6  ever‐married No 
Indonesia  2007  ever‐married  
Maldives  2009  ever‐married  
Nepal  2011  all  
Pakistan  2006‐7  ever‐married No 
Philippines  2008  all  
Timor‐Leste  2009‐10  all  

























Bolivia  2008  all  
Colombia  2010  all   
Dominican Republic 2007  all  
Guyana  2009  all  
Haiti  2012  all  
Honduras  2011‐12  all  
Nicaragua  2001  all  
Peru  2000  all  
Number of countries  8 8 
  TOTAL countries   57  57 46 
 
Web Table 3. Grouping of modern contraceptives by duration, ease of training and the actual time needed to deliver 
the method, excluding counselling 
Contraceptive 
methods Literature 
Our Initial Classification:  
Final 
Classification: 




provide method  







Female and male 
sterilisation 
Long-acting 
(permanent) Intensive (10) 20 minutes 
Sterilisation 
(permanent) 
Implant and IUD Long-acting Reversible (LARCs) Medium (8) 10 minutes LARCs  
Injectables Short-acting Medium (8) 10 minutes Injectables 
Oral contraceptive 






















Women in need 
Women using 
appropriate services 
with a classifiable 
sector 


















































Benin 83.0% 17.0% 7.2% 8.1% 1.7% 46.9% 53.1% 10.9% 53.7% 28.0% 1.1% 6.3% 
Burkina Faso 60.2% 39.8% 29.3% 8.8% 1.7% 76.9% 23.1% 5.2% 46.2% 48.4% 0.2% 0.0% 
Burundi 67.3% 32.7% 28.5% 3.7% 0.5% 88.5% 11.5% 28.3% 59.6% 8.5% 3.5% 0.0% 
Cameroon 61.1% 38.9% 7.8% 20.7% 10.4% 27.4% 72.6% 9.1% 36.9% 49.5% 4.6% 0.0% 
Chad 94.1% 5.9% 3.6% 2.1% 0.3% 63.2% 36.8% 20.5% 19.3% 40.7% 0.0% 19.5% 
Congo-B 77.1% 22.9% 5.0% 11.8% 6.0% 29.8% 70.2% 8.5% 54.4% 37.0% 0.0% 0.0% 
DRC 83.9% 16.1% 3.3% 9.9% 2.8% 25.1% 74.9% 14.4% 80.3% 5.1% 0.2% 0.0% 
Ethiopia 49.3% 50.7% 41.6% 7.4% 1.7% 84.8% 15.2% 66.4% 14.8% 6.4% 0.0% 12.4% 
Gabon 55.7% 44.3% 6.5% 25.5% 12.2% 20.4% 79.6% 4.6% 82.8% 11.8% 0.0% 0.9% 
Ghana 69.0% 31.0% 11.3% 14.9% 4.9% 43.1% 56.9% 10.8% 87.5% 1.0% 0.4% 0.4% 
Guinea 81.8% 18.2% 6.5% 7.0% 4.7% 48.4% 51.6% 9.0% 41.7% 49.3% 0.0% 0.0% 
Kenya 44.8% 55.2% 31.8% 22.0% 1.4% 59.2% 40.8% 52.9% 25.5% 9.2% 12.3% 0.0% 
Lesotho 32.5% 67.5% 37.9% 24.5% 5.0% 60.8% 39.2% 26.8% 7.8% 23.2% 17.9% 24.3% 
Liberia 74.2% 25.8% 13.1% 8.1% 4.6% 61.8% 38.2% 32.2% 32.2% 2.8% 0.0% 32.9% 
Madagascar 53.0% 47.0% 34.3% 10.9% 1.8% 75.9% 24.1% 61.1% 23.4% 14.9% 0.7% 0.0% 
Malawi 41.1% 58.9% 43.5% 14.7% 0.7% 74.7% 25.3% 13.7% 0.2% 12.6% 35.8% 37.6% 
Mali 81.6% 18.4% 9.6% 7.5% 1.3% 55.9% 44.1% 10.2% 82.7% 7.1% 0.0% 0.0% 
Mozambique 63.9% 36.1% 27.7% 4.4% 4.1% 86.3% 13.7% 18.2% 76.5% 5.3% 0.0% 0.0% 
Namibia 22.7% 77.3% 57.6% 16.4% 3.4% 77.9% 22.1% 31.8% 15.6% 52.5% 0.1% 0.0% 
Niger 81.1% 18.9% 12.8% 5.4% 0.8% 70.2% 29.8% 7.2% 76.9% 15.9% 0.0% 0.0% 
Nigeria 70.3% 29.7% 6.9% 18.6% 4.2% 27.2% 72.8% 17.1% 78.1% 3.9% 0.1% 0.8% 
Rwanda 38.1% 61.9% 56.9% 3.9% 1.1% 93.6% 6.4% 23.5% 40.7% 35.9% 0.0% 0.0% 
Sao Tome & Principe 53.7% 46.3% 40.1% 4.8% 1.3% 89.2% 10.8% 9.8% 0.0% 84.5% 0.0% 5.6% 
Senegal 71.3% 28.7% 23.9% 3.3% 1.5% 88.0% 12.0% 24.7% 68.9% 2.4% 4.0% 0.0% 
Sierra Leone 79.1% 20.9% 10.6% 8.3% 2.1% 56.1% 43.9% 30.4% 68.3% 1.3% 0.0% 0.0% 
Swaziland 34.7% 65.3% 29.1% 29.5% 6.6% 49.7% 50.3% 20.3% 9.9% 32.6% 20.1% 17.1% 
Tanzania 51.3% 48.7% 27.6% 14.8% 6.2% 65.1% 34.9% 4.7% 39.3% 36.6% 18.4% 1.0% 
Uganda 55.3% 44.7% 20.8% 22.7% 1.1% 47.8% 52.2% 82.7% 6.4% 10.7% 0.2% 0.0% 
Zambia 59.4% 40.6% 27.6% 10.6% 2.4% 72.2% 27.8% 20.3% 34.2% 38.3% 7.2% 0.0% 
Zimbabwe 22.7% 77.3% 56.8% 17.3% 3.2% 76.6% 23.4% 18.2% 42.8% 18.2% 18.7% 2.1% 
 









Women in need 
Women using 
appropriate services 
with a classifiable 
sector 




















































Albania 86.6% 13.4% 7.1% 5.4% 0.9% 56.7% 43.3% 2.5% 97.3% 0.2% 0.0% 0.0% 
Armenia 61.6% 38.4% 14.3% 23.6% 0.5% 37.7% 62.3% 2.7% 97.1% 0.2% 0.0% 0.0% 
Azerbaijan 80.1% 19.9% 14.3% 5.2% 0.3% 73.2% 26.8% 6.2% 93.0% 0.0% 0.0% 0.9% 
Egypt 19.9% 80.1% 47.7% 32.3% 0.1% 59.6% 40.4% 54.4% 39.7% 0.0% 2.8% 3.1% 
Jordan 42.8% 57.2% 23.9% 32.6% 0.7% 42.4% 57.6% 59.5% 26.4% 0.0% 0.0% 14.1% 
Moldova 45.3% 54.7% 37.5% 15.5% 1.6% 70.7% 29.3% 7.2% 90.4% 2.3% 0.0% 0.0% 
Morocco 30.3% 69.7% 39.3% 29.4% 1.0% 57.2% 42.8% 7.5% 92.5% 0.0% 0.0% 0.0% 
Turkey 47.4% 52.6% 30.4% 21.7% 0.5% 58.3% 41.7% 35.9% 60.0% 3.4% 0.0% 0.8% 
Ukraine 33.6% 66.4% 48.8% 6.6% 11.1% 88.2% 11.8% 15.4% 36.8% 47.8% 0.0% 0.0% 






Bangladesh 30.3% 69.7% 34.5% 33.9% 1.3% 50.4% 49.6% 6.6% 68.5% 10.7% 5.3% 8.8% 
Cambodia 48.4% 51.6% 26.6% 18.3% 6.7% 59.3% 40.7% 45.5% 40.0% 14.4% 0.0% 0.0% 
India 30.0% 70.0% 49.4% 16.9% 3.7% 74.6% 25.4% 64.5% 29.9% 2.4% 0.0% 3.2% 
Indonesia 23.0% 77.0% 17.1% 55.4% 4.5% 23.6% 76.4% 84.0% 12.1% 3.9% 0.0% 0.0% 
Maldives 56.7% 43.3% 27.4% 11.6% 4.4% 70.3% 29.7% 23.2% 73.4% 3.4% 0.0% 0.0% 
Nepal 43.8% 56.2% 38.7% 16.0% 1.4% 70.7% 29.3% 27.1% 42.3% 0.8% 0.0% 29.7% 
Pakistan 60.3% 39.7% 19.1% 16.0% 4.5% 54.4% 45.6% 49.2% 25.2% 25.6% 0.0% 0.0% 
Philippines 54.0% 46.0% 21.3% 24.3% 0.4% 46.7% 53.3% 21.7% 74.9% 3.3% 0.0% 0.2% 
Timor-Leste 61.6% 38.4% 33.9% 4.0% 0.4% 89.4% 10.6% 79.9% 8.9% 4.3% 0.0% 6.9% 
Vietnam 33.4% 66.6% 57.0% 9.0% 0.5% 86.4% 13.6% 34.7% 65.3% 0.0% 0.0% 0.0% 















Bolivia 57.6% 42.4% 20.7% 20.4% 1.3% 50.4% 49.6% 31.4% 57.2% 0.0% 0.0% 11.4% 
Colombia 16.1% 83.9% 47.1% 34.7% 2.1% 57.5% 42.5% 43.0% 55.1% 2.0% 0.0% 0.0% 
Dominican Republic 17.6% 82.4% 42.2% 36.9% 3.4% 53.4% 46.6% 65.8% 31.7% 2.3% 0.0% 0.2% 
Guyana 40.1% 59.9% 29.1% 23.6% 7.2% 55.2% 44.8% 31.2% 52.6% 14.1% 0.2% 1.8% 
Haiti 54.6% 45.4% 16.6% 23.1% 5.8% 41.9% 58.1% 38.2% 21.2% 13.9% 0.0% 26.7% 
Honduras 22.6% 77.4% 40.2% 31.4% 5.8% 56.2% 43.8% 50.7% 45.0% 3.9% 0.0% 0.3% 
Nicaragua 22.9% 77.1% 49.4% 25.7% 2.0% 65.8% 34.2% 48.9% 36.2% 1.0% 0.0% 13.9% 
Peru 40.7% 59.3% 47.1% 11.3% 1.0% 80.7% 19.3% 44.7% 42.7% 0.7% 0.0% 11.8% 
 
